REFERENCES
- Kaneda N, Nagata H, Furuta T, et al. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990; 50: 1715–1720, [PUBMED], [INFOTRIEVE], [CSA]
- Pratt C B, Stewart C, Santana V M, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 1994; 12: 539–543, [PUBMED], [INFOTRIEVE], [CSA]
- Tsuchida Y, Shitara T. Topotecan and irinotecan in the treatment of pediatric solid tumors. Curr Pediatr Rev 2005; 1: 55–61, [CSA], [CROSSREF]
- Verwyij J. Topoisomerase I inhibitors and other new cytotoxic drugs. Eur J Cancer 1995; 5: 828–830, [CSA], [CROSSREF]
- Ohno R, Okada K, Masaoka T, et al. An early phase II study of CPT-11, a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990; 8: 1907–1912, [PUBMED], [INFOTRIEVE], [CSA]
- Fukutani K, Wakui A, Nakao M, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother 1994; 21: 1033–1038, [CSA]
- Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 1992; 10: 1225–1229, [PUBMED], [INFOTRIEVE], [CSA]
- Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992; 10: 16–20, [PUBMED], [INFOTRIEVE], [CSA]
- Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85–91, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Nishida M, Tsunoda H, Ichikawa Y, Yoshikawa H. Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma. Int J Clin Oncol 2004; 9: 403–405, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Moertel C G, Schut A J, Reitemeier R J, et al. Phase II study of camptothecin in the treatment of advanced gastro-intestinal cancer. Cancer Chemother Rep 1992; 56: 95–101, [CSA]
- Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909–913, [PUBMED], [INFOTRIEVE], [CSA]
- Rosoff P M, Bayliff S. Successful clinical response to irinotecan in desmoplastic round blue cell tumor. Med Pediatr Oncol 1999; 33: 500–503, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Furman W L, Stewart C F, Poquette C A, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999; 17: 1815–1824, [PUBMED], [INFOTRIEVE], [CSA]
- Blaney S, Berg S L, Pratt C, et al. Phase I study of irinotecan in pediatric patients: a Pediatric Oncology Group study. Clin Cancer Res 2001; 7: 32–37, [PUBMED], [INFOTRIEVE], [CSA]
- Vassal G, Doz F, Frappaz D, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 2003; 21: 3844–3852, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mugishima H, Matsunaga T, Yagi K, et al. Phase I study of irinotecan in pediatric patients with malignant solid tumors. J Pediatr Hematol Oncol 2002; 24: 94–100, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Matthay K K, Villablanca J G, Seeger R C, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341: 1165–1173, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kawa K, Ohnuma N, Kaneko M, et al. Long-term survivors of advanced neuroblastoma with MYCN amplification: a report of 19 patients surviving disease-free for more than 66 months. J Clin Oncol 1999; 17: 3216–3220, [PUBMED], [INFOTRIEVE], [CSA]
- Komuro H, Li P, Tsuchida Y, et al. Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma. Med Pediatr Oncol 1994; 23: 487–492, [PUBMED], [INFOTRIEVE], [CSA]
- Kamii Y, Tsuchida Y, Yokomori K. Effects of CPT-11 on a human rhabdomyosarcoma in nude mice and in culture. Int J Pediatr Hematol Oncol 1996; 3: 201–205, [CSA]
- Choi S H, Yang H W, Tsuchida Y. Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice. Cancer Lett 1998; 124: 15–21, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Vassal G, Doz F, Frappaz D, et al. A phase II study of irinotecan (CPT-11) in children with relapsed or refractory neuroblastoma. Med Pediatr Oncol 2002; 39: 257, [CSA]
- Society of Japanese Pharmacopoeia. Summary Basis of Approval No 1, Irinotecan Hydrochloride. Yakuji Nippo, Tokyo 1995
- Oken M M, Greech R H, Tormey D C, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655, [PUBMED], [INFOTRIEVE], [CSA]
- Therasse P, Arbuck S G, Eisenhauer E A, et al. New guidelines to evaluate the response to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205–216, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cosetti M, Wexler L H, Calleja E, et al. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol 2002; 24: 101–105, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Shitara T, Shimada A, Tsuchida Y, et al. Successful clinical response to irinotecan in relapsed neuroblastoma. Med Pediatr Oncol 2003; 40: 126–128, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Houghton P J, Cheshire P J, Hallman J D, Jr, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995; 36: 393–403, [PUBMED], [INFOTRIEVE], [CSA]
- COG-ARST0121,
- Raney R B, Anderson J R, Barr F R, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001; 23: 215–220, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Stevens M CG. Rhabdomyosarcoma. Cancer in Children: Clinical Management, P A Voûte, C Kalifa, A Barrett. Oxford University Press, Oxford, UK 1998; 193–215